These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 1860020)

  • 1. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
    Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
    Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate.
    Marder SR; Aravagiri M; Wirshing WC; Wirshing DA; Lebell M; Mintz J
    Schizophr Res; 2002 Jan; 53(1-2):25-30. PubMed ID: 11728835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
    Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
    Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome.
    Marder SR; Van Putten T; Mintz J; Lebell M; McKenzie J; May PR
    Arch Gen Psychiatry; 1987 Jun; 44(6):518-21. PubMed ID: 3555385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute dystonia during fixed-dose neuroleptic treatment.
    Singh H; Levinson DF; Simpson GM; Lo ES; Friedman E
    J Clin Psychopharmacol; 1990 Dec; 10(6):389-96. PubMed ID: 2286708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate.
    Marder SR; Hawes EM; Van Putten T; Hubbard JW; McKay G; Mintz J; May PR; Midha KK
    Psychopharmacology (Berl); 1986; 88(4):480-3. PubMed ID: 3085136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate.
    Miller RS; Peterson GM; McLean S; Westhead TT; Gillies P
    J Clin Pharm Ther; 1995 Apr; 20(2):55-62. PubMed ID: 7650075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
    Odejide OA; Aderounmu AF
    J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
    Walker CA
    Pharmatherapeutica; 1983; 3(5):289-93. PubMed ID: 6133287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesia.
    Glazer WM
    Schizophr Res; 1988; 1(6):425-9. PubMed ID: 3154530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluphenazine plasma levels, dosage, efficacy, and side effects.
    Levinson DF; Simpson GM; Lo ES; Cooper TB; Singh H; Yadalam K; Stephanos MJ
    Am J Psychiatry; 1995 May; 152(5):765-71. PubMed ID: 7726317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia.
    Russell N; Landmark J; Merskey H; Turpin T
    Can J Psychiatry; 1982 Nov; 27(7):593-6. PubMed ID: 7172160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluphenazine decanoate and tardive dyskinesia: a possible association.
    Csernansky JG; Grabowski K; Cervantes J; Kaplan J; Yesavage JA
    Am J Psychiatry; 1981 Oct; 138(10):1362-5. PubMed ID: 7294195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suicide associated with akathisia and depot fluphenazine treatment.
    Shear MK; Frances A; Weiden P
    J Clin Psychopharmacol; 1983 Aug; 3(4):235-6. PubMed ID: 6886035
    [No Abstract]   [Full Text] [Related]  

  • 18. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.
    Kane JM; Rifkin A; Woerner M; Reardon G; Sarantakos S; Schiebel D; Ramos-Lorenzi J
    Arch Gen Psychiatry; 1983 Aug; 40(8):893-6. PubMed ID: 6347119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Side effects during long-term treatment with depot antipsychotic medication.
    Cookson JC
    Clin Neuropharmacol; 1991; 14 Suppl 2():S24-30; discussion S30-2. PubMed ID: 1751940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs and benefits of two doses of fluphenazine.
    Marder SR; Van Putten T; Mintz J; McKenzie J; Lebell M; Faltico G; May PR
    Arch Gen Psychiatry; 1984 Nov; 41(11):1025-9. PubMed ID: 6437365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.